Register to receive a free U.S. Market Report Suite for Infusion Therapy Device – MedSuite report synopsis and brochure
According to a new series of reports on the U.S. market for infusion therapy devices by iData Research, manufacturing and design defects leading to occasional product recalls hamper steady sales in the country. Furthermore, persistence of plastic PVC-based materials containing potentially harmful DEHP leaves customers in doubt and pushes them to other treatment options without the use of advanced medical devices.
Despite these challenges, the industry is gradually introducing more stringent rules and adopting new standards for safer practices. This progress is being achieved through improving national standards of care, such as via the Infusion Therapy Standards of Practice and the Policies and Procedures for Infusion Nursing, as well as through upgrading policies of individual care providers. These developments have led to increased replacement rates of equipment already in use and the introduction of new, safer, and more efficient technologies in the market. More R&D teams and practitioners are working to identify potential problems across the full spectrum of devices for IV therapy and to develop options to improve both technology and procedures.
“In the coming years, IV therapy will continue to be an increasingly effective method of treatment, presenting opportunities for both industry veterans and new entrants,” explains Jeffrey Wong, Strategic Analyst Manager at iData Research. “Corporate consolidation will increase overall R&D spending and lead to the development of more effective and efficient devices, further growing the market volume and penetration.”
The infusion therapy device market in the U.S. is a mixture of single-use devices, such as IV sets and needleless connectors, and capital equipment, such as IV pumps and software. The IV set segment accounted for the largest portion of the overall infusion therapy device market due to the sheer volume of IV sets sold. However, the market for infusion pumps is comparable to the IV set market in value. The infusion pump market is highly saturated and the majority of units sold go towards replacing existing systems.
Becton Dickinson is the leading competitor in the U.S. infusion therapy device market. The company’s Alaris® intravenous (IV) set product line includes primary, secondary and IV extension sets, which are bundled with their Alaris® large volume and syringe infusion pumps. Becton Dickinson has benefited from several product recalls by their competitors in the infusion pump market, and strategic acquisitions of companies with complementary product lines. Additional competitors in the U.S. infusion therapy device market include ICU Medical/Hospira, Baxter, B.Braun, Smiths Medical, Fresenius, Nexus Medical, Halyard Health, Codan USA, GVS, Pall Corporation, Medtronic, Merck Millipore, Vygon and ITW Filtertek among others.
For Further Information
The full report suite on the U.S. market for infusion therapy devices includes infusion pumps, intravenous (IV) sets, needleless connectors (NLCs) and stopcocks. These four categories are further segmented based on specific distinguishing categories. The infusion pump market is segmented into categories based on the type of pump, such large volume, syringe, electronic ambulatory and disposable infusion pumps. The intravenous set market is segmented by tubing type, such as primary IV, secondary IV and IV extension sets. The iData series on the market for infusion therapy devices covers the U.S., Australia, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.
